Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionovo has said that the higher doses of its innovative breast cancer drug candidate, BZL101 was well tolerated in an ongoing Phase I/II trial.
Subscribe to our email newsletter
As a result, the company will be extending the dose escalation portion of the study longer than previously communicated.
Mary Tagliaferri, Bionovo’s president and chief medical officer, said: “As a result of this positive news, we will continue the dose escalation, so long as we continue to see favorable tolerability and safety, after which we will transition to the full Phase II study component.”